Withaferin A inhibits activation of signal transducer and activator of transcription 3 in human breast cancer cells

Carcinogenesis

Volumn 31, Issue 11, 2010, Pages 1991-1998

  Lee, Joomin ^a   Hahm, Eun Ryeong ^a   Singh, Shivendra V ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; JANUS KINASE 2; STAT3 PROTEIN; TRANSCRIPTION FACTOR; TYROSINE; WITHAFERIN A;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CELL STIMULATION; CELL STRAIN MCF 7; CONTROLLED STUDY; DIMERIZATION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; TRANSCRIPTION REGULATION;

APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; DIMERIZATION; FEMALE; HUMANS; INTERLEUKIN-6; LUCIFERASES; PHOSPHORYLATION; STAT3 TRANSCRIPTION FACTOR; TUMOR CELLS, CULTURED; WITHANOLIDES;

EID: 78149239365     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgq175     Document Type: Article

References (50)

1. Jemal, A. et al. (2008) Cancer statistics, 2008. CA Cancer J. Clin., 58, 71-96.
2. Desantis, C. et al. (2008) Temporal trends in breast cancer mortality by state and race. Cancer Causes Control, 19, 537-545.
3. van de Ven, S.M. et al. (2008) Optical imaging of the breast. Cancer Imaging, 8, 206-215.
4. Muñoz, M. et al. (2008) Evaluation of international treatment guidelines and prognostic tests for the treatment of early breast cancer. Cancer Treat. Rev., 34, 701-709.
5. Kelsey, J.L. et al. (1993) Reproductive factors and breast cancer. Epidemiol. Rev., 15, 36-47.
6. Hulka, B.S. et al. (1995) Breast cancer: cause and prevention. Lancet, 346, 883-887.
7. Kelsey, J.L. et al. (1996) Epidemiology and prevention of breast cancer. Annu. Rev. Public Health, 17, 47-67.
8. Fisher, B. et al. (1998) Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J. Natl Cancer Inst., 90, 1371-1388.
9. Cuzick, J. et al. (2002) First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet, 360, 817-824.
10. Land, S.R. et al. (2006) Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA, 295, 2742-2751.
11. Newman, D.J. et al. (2003) Natural products as sources of new drugs over the period 1981-2002. J. Nat. Prod., 66, 1022-1037.
12. Mishra, L.C. et al. (2000) Scientific basis for the therapeutic use of Withania somnifera (ashwagandha): a review. Altern. Med. Rev., 5, 334-346.
13. Winters, M. (2006) Ancient medicine, modern use: Withania somnifera and its potential role in integrative oncology. Altern. Med. Rev., 11, 269-277.
14. Agarwal, R. et al. (1999) Studies on immunomodulatory activity ofWithania somnifera (Ashwagandha) extract in experimental immune inflammation. J. Ethnopharmacol., 67, 27-35.
15. Gupta, S.K. et al. (2004) Cardioprotection from ischemia and reperfusion injury by Withania somnifera: a hemodynamic, biochemical and histopathological assessment. Mol. Cell. Biochem., 260, 39-47.
16. Ahmad, M. et al. (2005) Neuroprotective effects of Withania somnifera on 6-hydroxydopamine induced Parkinsonism in rats. Hum. Exp. Toxicol., 24, 137-147.
17. Owais, M. et al. (2005) Antibacterial efficacy of Withania somnifera (Ashwagandha) an indigenous medicinal plant against experimental murine salmonellosis. Phytomedicine, 12, 229-235.
18. Rasool, M. et al. (2006) Immunomodulatory role of Withania somnifera root powder on experimental induced inflammation: an in vivo and in vitro study. Vascul. Pharmacol., 44, 406-410.
19. Devi, P.U. et al. (2000) Radiosensitization of a mouse melanoma by withaferin A: in vivo studies. Indian J. Exp. Biol., 38, 432-437.
20. Devi, P.U. et al. (1995) In vivo growth inhibitory and radiosensitizing effects of withaferin A on mouse Ehrlich ascites carcinoma. Cancer Lett., 95, 189-193.
21. Ichikawa, H. et al. (2006) Withanolides potentiate apoptosis, inhibit invasion, and abolish osteoclastogenesis through suppression of nuclear factor-kappaB (NF-kappaB) activation and NF-kappaB-regulated gene expression. Mol. Cancer Ther., 5, 1434-1445.
22. Kaileh, M. et al. (2007) Withaferin A strongly elicits IkappaB kinase beta hyperphosphorylation concomitant with potent inhibition of its kinase activity. J. Biol. Chem., 282, 4253-4264.
23. Mohan, R. et al. (2004) Withaferin A is a potent inhibitor of angiogenesis. Angiogenesis, 7, 115-122.
24. Falsey, R.R. et al. (2006) Actin microfilament aggregation induced by withaferin A is mediated by annexin II. Nat. Chem. Biol., 2, 33-38.
25. Yang, H. et al. (2007) The tumor proteasome is a primary target for the natural anticancer compound withaferin A isolated from "Indian winter cherry". Mol. Pharmacol., 71, 426-437.
26. Srinivasan, S. et al. (2007) Par-4-dependent apoptosis by the dietary compound withaferin A in prostate cancer cells. Cancer Res., 67, 246-253.
27. Malik, F. et al. (2007) Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic cell death of human myeloid leukemia HL-60 cells by a dietary compound withaferin A with concomitant protection by N-acetyl cysteine. Apoptosis, 12, 2115-2133.
28. Stan, S.D. et al. (2008) Withaferin A causes FOXO3a- and Bim-dependent apoptosis and inhibits growth of human breast cancer cells in vivo. Cancer Res., 68, 7661-7669.
29. Stan, S.D. et al. (2008) Ayurvedic medicine constituent withaferin A causes G2 and M phase cell cycle arrest in human breast cancer cells. Nutr. Cancer, 60 (suppl. 1), 51-60.
30. Oh, J.H. et al. (2008) Induction of apoptosis by withaferin A in human leukemia U937 cells through down-regulation of Akt phosphorylation. Apoptosis, 13, 1494-1504.
31. Mandal, C. et al. (2008) Withaferin A induces apoptosis by activating p38 mitogen-activated protein kinase signaling cascade in leukemic cells of lymphoid and myeloid origin through mitochondrial death cascade. Apoptosis, 13, 1450-1464.
32. Yu, Y. et al. (2010)Withaferin A targets heat shock protein 90 in pancreatic cancer cells. Biochem. Pharmacol., 79, 542-551.
33. Turkson, J. et al. (2000) STAT proteins: novel molecular targets for cancer drug discovery. Oncogene, 19, 6613-6626.
34. Al Zaid Siddiquee, K. et al. (2008) STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res., 18, 254-267.
35. Yu, H. et al. (2007) Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat. Rev. Immunol., 7, 41-51.
36. Garcia, R. et al. (1997) Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth Differ., 8, 1267-1276.
37. Ling, X. et al. (2005) Knockdown of STAT3 expression by RNA interference inhibits the induction of breast tumors in immunocompetent mice. Cancer Res., 65, 2532-2536.
38. Diaz, N. et al. (2006) Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression. Clin. Cancer Res., 12, 20-28.
39. 2/M arrest and inducing apoptosis. Carcinogenesis, 24, 891-897.
40. Shin, D.S. et al. (2009) Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells. Cancer Res., 69, 193-202.
41. Xiao, D. et al. (2004) Diallyl trisulfide-induced apoptosis in human prostate cancer cells involves c-Jun N-terminal kinase and extracellularsignal regulated kinase-mediated phosphorylation of Bcl-2. Oncogene, 23, 5594-5606.
42. Heinrich, P.C. et al. (1998) Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem. J., 334, 297-314.
43. Hsieh, F.C. et al. (2005) Evaluation of potential Stat3-regulated genes in human breast cancer. Biochem. Biophys. Res. Commun., 335, 292-299.
44. Yang, S.F. et al. (2007) Altered p-STAT3 (Tyr705) expression is associated with histological grading and intratumour microvessel density in hepatocellular carcinoma. J. Clin. Pathol., 60, 642-648.
45. Sheen-Chen, S.M. et al. (2008) Prognostic value of signal transducers and activators of transcription 3 in breast cancer. Cancer Epidemiol. Biomarkers Prev., 17, 2286-2290.
46. Walker, S.R. et al. (2009) Reciprocal effects of STAT5 and STAT3 in breast cancer. Mol. Cancer Res., 7, 966-976.
47. Hawthorne, V.S. et al. (2009) ErbB2-mediated Src and signal transducer and activator of transcription 3 activation leads to transcriptional up-regulation of p21Cip1 and chemoresistance in breast cancer cells. Mol. Cancer Res., 7, 592-600.
48. Barbieri, I. et al. (2010) Constitutively active Stat3 enhances neu-mediated migration and metastasis in mammary tumors via upregulation of Cten. Cancer Res., 70, 2558-2567.
49. Lou, W. et al. (2000) Interleukin-6 induces prostate cancer cell growth accompanied by activation of STAT3 signaling pathway. Prostate, 42, 239-242.
50. Real, P.J. et al. (2002) Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene, 21, 7611-7618.